Acrivon Therapeutics, Inc. ACRV
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
Acrivon Therapeutics, Inc. (ACRV) is a healthcare company listed in the US with a market value of about $62M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -42%.
About Acrivon Therapeutics
Acrivon Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 834% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$78M | -$81M | -$60M | -$31M | -$16M |
| Free cash flow | -$65M | -$68M | -$44M | -$32M | -$14M |
| EPS (diluted) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| Net margin | — | — | — | — | — |
| ROIC | -73.0% | -39.1% | -42.1% | -14.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Acrivon Therapeutics pay a dividend?
Not currently.
Is Acrivon Therapeutics a good stock to buy?
We do not give buy or sell advice. Acrivon Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.